Ascendis Pharma A/S (ASND)
243.37
+0.38
(+0.16%)
USD |
NASDAQ |
Oct 23, 16:00
243.25
-0.12
(-0.05%)
After-Hours: 20:00
Ascendis Pharma Price to Book Value : 9.732 for Oct. 23, 2026
Price to Book Value Chart
Historical Price to Book Value Data
| Date | Value |
|---|---|
| October 23, 2026 | 9.732 |
| October 22, 2026 | 9.717 |
| October 21, 2026 | 9.553 |
| October 20, 2026 | 9.370 |
| October 19, 2026 | 9.195 |
| October 16, 2026 | 9.007 |
| October 15, 2026 | 9.062 |
| October 14, 2026 | 9.077 |
| October 13, 2026 | 8.926 |
| October 12, 2026 | 9.077 |
| October 09, 2026 | 9.166 |
| October 08, 2026 | 8.905 |
| October 07, 2026 | 9.134 |
| October 06, 2026 | 9.039 |
| October 05, 2026 | 9.118 |
| October 02, 2026 | 9.112 |
| October 01, 2026 | 9.090 |
| September 30, 2026 | 9.110 |
| September 29, 2026 | 9.12 |
| September 28, 2026 | 9.199 |
| September 25, 2026 | 9.021 |
| September 24, 2026 | 9.225 |
| September 23, 2026 | 8.922 |
| September 22, 2026 | 9.500 |
| September 21, 2026 | 9.501 |
| Date | Value |
|---|---|
| September 18, 2026 | 9.466 |
| September 17, 2026 | 9.559 |
| September 16, 2026 | 9.904 |
| September 15, 2026 | 9.588 |
| September 14, 2026 | 10.59 |
| September 11, 2026 | 10.54 |
| September 10, 2026 | 10.45 |
| September 09, 2026 | 10.43 |
| September 08, 2026 | 10.80 |
| September 04, 2026 | 10.82 |
| September 03, 2026 | 10.84 |
| September 02, 2026 | 10.69 |
| September 01, 2026 | 10.41 |
| August 31, 2026 | 10.52 |
| August 28, 2026 | 9.913 |
| August 27, 2026 | 9.971 |
| August 26, 2026 | 10.01 |
| August 25, 2026 | 10.12 |
| August 24, 2026 | 10.07 |
| August 21, 2026 | 10.13 |
| August 20, 2026 | 10.19 |
| August 19, 2026 | 10.38 |
| August 18, 2026 | 9.951 |
| August 17, 2026 | 9.893 |
| August 14, 2026 | 9.937 |
Price to Book Ratio Definition
Price to book value is a valuation ratio that is measured by stock price / book value per share. The book value is essentially the tangible accounting value of a firm compared to the market value that is shown.
Price to Book Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Price to Book Value Benchmarks
| BioMarin Pharmaceutical, Inc. | 1.713 |
| Novo Nordisk A/S | 5.101 |
| Evaxion AS | 3.290 |
| Genmab A/S | 4.389 |
| Zealand Pharma A/S | 0.8591 |
Price to Book Value Related Metrics
| PE Ratio | 18.54 |
| PS Ratio | 12.71 |
| Price to Free Cash Flow | 39.90 |
| Price | 243.37 |
| Earnings Yield | 5.39% |
| Market Cap | 15.98B |
| Operating PE Ratio | 123.17 |
| Normalized PE Ratio | 18.54 |